Scoop: Novartis disbands its pioneering cell and gene therapy unit
Novartis is dissolving its high-profile cell and gene therapy unit operating under the guiding hand of Usman “Oz” Azam, Endpoints has learned.
Azam has issued a note to the 400 staffers in the group, which was obtained by Endpoints, that says:
“The risk of embarking on a new adventure in uncharted territory is that things don’t always work out as envisioned. Today, I have the unfortunate task of announcing that we are dissolving the Cell and Gene Therapies Unit.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters